Worldwide, about 65 million people are estimated to have epilepsy. Epidemiologic studies
are necessary to define the full public health burden of epilepsy; to set public health and …

Children with developmental disabilities are at increased risk for epilepsy with a prevalence
rate higher than the general population. Some of the more common developmental …

Epilepsy occurs at a higher incidence and is more prevalent in people with an intellectual
disability than in the general population. Nonetheless, we have insufficient knowledge of the …

Objective: We retrospectively examined treatment records of developmentally disabled
adults with highly refractory epilepsy to determine whether any combinations of 8 of the most …

Patients who have developmental disabilities and epilepsy can be safely treated in a
general dental practice. A thorough medical history should be taken and updated at every …

Purpose: to describe the population pharmacokinetics of lamotrigine (LTG) in
developmentally disabled (DD) patients with epilepsy and (2) to determine if there is an …

This study evaluated the effects of lamotrigine as adjunctive therapy for refractory epilepsy in
patients with mental retardation. Patients with epilepsy and mental retardation having …

Purpose We describe the effectiveness of lacosamide as adjunctive therapy in patients with
epilepsy and an intellectual disability. This information is relevant, as few data exist …

Childhood-onset epilepsy is associated with psychiatric and cognitive difficulties and with
poor social outcomes in adulthood. Some antiepileptic drugs adversely affect behavior in …

We investigated whether a combination of risk factors affects the free phenytoin (PHT)
fraction by multiple regression analyses in 30 patients with severe motor and intellectual …